CSI Market
Sign In | Register

Lixte Biotechnology Holdings Inc (LIXT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LIXT Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Lixte Biotechnology Holdings Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-8.46
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.76
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Share Based Compensation Cost-
Research And Development Stock Based Cost-
Cost Of Warrant Extension-
Increase Decrease In Grant Receivable-
Increase Decrease In Advances On Research And Development Contract Services-
Increase Decrease In Liquidated Damages Payable Under Registration Rights Agreement-
General And Administrative Stock Based Expenses-
Research And Development Stock Based Expenses-
Fair Value Of Warrant Extension-
General And Administrative Stock Based Compensation Expenses-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect-
Noncash Operating Lease Cost0.12
Fair Value Of Shares Issued For Services0.05
Increase Decrease In Research And Development Contract Liabilities0.01
Increase Decrease In Operating Lease Liability0.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.11
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.06
Other Working Capital0.07
Other Noncash Income (Expense)0.00
Other net-0.22
Payments for (Proceeds from) Other Operating Activities4.46
Discontinued operations0.00
Net Cash flow from Operating Activities-3.44
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Capitalized Transaction Costs-0.02
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-6.52
Discontinued operations0.00
Net Cash Flow from Investing Activities-6.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.53
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Sale Of Common Stock To Consulting Firm-
Stock Issued During Period Value Issued For Services-
Proceeds From Issuance Of Notes Payable To Consultants-
Sales Of Series Convertible Preferred Stock Value-
Proceeds From Sale Of Convertible Preferred Stock-
Payment Of Deferred Offering Costs-
Repayment Of Deferred Offering Costs-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities17.53
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-3.44
Total Cash Flow7.56
4 historic quarters locked

Sign in to unlock the full Lixte Biotechnology Holdings Inc cash flow history.

Sign In Create Free Account

About Nomad Power Solutions Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038001

Figures are derived from filed reports and may be restated. Historical data is subject to revision.